Trial · NCT07115641
Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis
NCT07115641, Not applicable, Not yet recruiting, Wangjing Hospital, China Academy of Chinese Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis. Trials, record NCT07115641. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07115641
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis
- NCT number
- NCT07115641
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 240 participants, estimated
- Lead sponsor
- Wangjing Hospital, China Academy of Chinese Medical Sciences
- Conditions
- Rheumatoid Arthritis
- Interventions
- Huoluo Pills, Iguratimod Tablets
- First posted
- 2025-08-11
- Last updated
- 2025-08-11
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of subjects achieving ACR20 | At the end of the treatment (on the 84th day) | ACR20: The improvement degree of the number of tender joints and the number of swollen joints is ≥20%, and the improvement degree of at least 3 items among the remaining 5 items is ≥20%. |
| Secondary | The change of Disease Activity Score in 28 Joints-C-Reactive Protein（DAS28-CRP） score compared with the baseline | At the end of the treatment (on the 84th day) | DAS28-CRP=0.56×sqrt（TJC28）+0.28×sqrt（SJC28）+0.36×ln（CRP+1）+0.014×GH+0.96 * TJC28: Number of tender joints among 28 joints; * SJC28: Number of swollen joints among 28 joints; * ESR: Erythrocyte Sedimentation Rate; * CRP: C-reactive Protein; * GH: Patient's global assessment of disease activity (VAS score, unit: 100mm). Disease activity DAS28-CRP thresholds: * High: \> 4.1; * Moderate: \> 2.7 and ≤ 4.1; * Low: \> 2.3 and ≤ 2.7; * Remission: ≤ 2.3 |
| Secondary | The proportion of subjects achieving ACR20 | By the 28th day of treatment | ACR20: The improvement degree of the number of tender joints and the number of swollen joints is ≥20%, and the improvement degree of at least 3 items among the remaining 5 items is ≥20%. |
| Secondary | The change of Disease Activity Score in 28 Joints-C-Reactive Protein（DAS28-CRP） score compared with the baseline | By the 28th day of treatment | DAS28-CRP=0.56×sqrt（TJC28）+0.28×sqrt（SJC28）+0.36×ln（CRP+1）+0.014×GH+0.96 - TJC28: Number of tender joints among 28 joints; - SJC28: Number of swollen joints among 28 joints; - ESR: Erythrocyte Sedimentation Rate; - CRP: C-reactive Protein; - GH: Patient's global assessment of disease activity (VAS score, unit: 100mm). Disease activity DAS28-CRP thresholds: - High: \> 4.1; - Moderate: \> 2.7 and ≤ 4.1; - Low: \> 2.3 and ≤ 2.7; - Remission: ≤ 2.3 |
| Secondary | The remission rate of Disease Activity Score in 28 Joints-C-Reactive Protein（DAS28-CRP） | When treating up to the 28th and 84th days | |
| Secondary | The low activity rate of Disease Activity Score in 28 Joints-C-Reactive Protein（DAS28-CRP） | When treating up to the 28th and 84th days | |
| Secondary | The remission rate of Disease Activity Score in 28 Joints-Erythrocyte Sedimentation Rate（DAS28-ESR） | When treating up to the 28th and 84th days | |
| Secondary | The low activity rate of Disease Activity Score in 28 Joints-Erythrocyte Sedimentation Rate（DAS28-ESR） | When treating up to the 28th and 84th days | |
| Secondary | The change of Disease Activity Score in 28 Joints-Erythrocyte Sedimentation Rate（DAS28-ESR） score compared with the baseline | When treating up to the 28th and 84th days | DAS28-ESR=0.56×sqrt（TJC28）+0.28×sqrt（SJC28）+0.70×ln（ESR）+0.014×GH * TJC28: Number of tender joints among 28 joints; * SJC28: Number of swollen joints among 28 joints; * ESR: Erythrocyte Sedimentation Rate; * CRP: C-reactive Protein; * GH: Patient's global assessment of disease activity (VAS score, unit: 100mm). Disease activity DAS28-ESR thresholds: * High: \> 5.1; * Moderate: \> 3.2 and ≤ 5.1; * Low: \> 2.6 and ≤ 3.2; * Remission: ≤ 2.6 |
| Secondary | The proportion of subjects with ACR50 | When treating up to the 28th and 84th days | ACR50: The improvement degree of the number of tender joints and the number of swollen joints is ≥50%, and the improvement degree of at least 3 items among the remaining 5 items is ≥50%. |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07115641
GET https://conductscience.org/api/trials/v1/NCT07115641/registered?page=2